➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Merck
Baxter
Colorcon
Moodys
McKinsey
Mallinckrodt

Last Updated: September 22, 2020

DrugPatentWatch Database Preview

Details for Patent: 9,108,975

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Which drugs does patent 9,108,975 protect, and when does it expire?

Patent 9,108,975 protects SYMPROIC and is included in one NDA.

This patent has forty-one patent family members in twenty-four countries.

Summary for Patent: 9,108,975
Title:Crystal of 6,7-unsaturated-7-carbamoyl morphinan derivative and method for producing the same
Abstract: Stable crystalline forms of a compound represented by the formula (IA): ##STR00001## an acid addition salt, and/or a solvate thereof are provided by the present invention. Said crystalline forms are extremely useful as materials for preparing medicines. Novel processes for preparing 6,7-unsaturated-7-carbamoyl morphinan derivatives are also provided by the present invention.
Inventor(s): Tamura; Yoshinori (Toyonaka, JP), Noguchi; Kouichi (Amagasaki, JP), Inagaki; Masanao (Toyonaka, JP), Morimoto; Kenji (Toyonaka, JP), Haga; Nobuhiro (Toyonaka, JP), Oda; Shinichi (Iwate-ken, JP), Omura; Sohei (Amagasaki, JP)
Assignee: Shionogi & Co., LTD. (Osaka, JP)
Application Number:13/884,770
Patent Claim Types:
see list of patent claims
Composition; Compound;

Drugs Protected by US Patent 9,108,975

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Bdsi SYMPROIC naldemedine tosylate TABLET;ORAL 208854-001 Mar 23, 2017 RX Yes Yes   Start Trial   Start Trial Y Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 9,108,975

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Japan2010-253688Nov 12, 2010
PCT Information
PCT FiledNovember 11, 2011PCT Application Number:PCT/JP2011/076034
PCT Publication Date:May 18, 2012PCT Publication Number: WO2012/063933

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
AstraZeneca
Boehringer Ingelheim
Dow
Merck
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.